Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
International Journal of Cell Biology|July 4, 2012
Chelators in the treatment of iron accumulation in Parkinson's diseaseRoss B Mounsey, Peter TeismannParkinson'S Disease|January 15, 2011
Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotectionRoss B Mounsey, Peter TeismannNaunyn-Schmiedeberg'S Archives of Pharmacology|June 14, 2011
MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stressYa-Ching Hsieh, Ross B Mounsey, Peter TeismannExperimental Neurology|March 16, 2012
Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's diseaseHeather L Martin, Ross B Mounsey, Sarah Mustafa, et al.Experimental Neurology|August 6, 2015
Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseRoss B Mounsey, Sarah Mustafa, Lianne Robinson, et al.Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.Brain : a Journal of Neurology|July 26, 2013
Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanismsCeline Perier, Andreas Bender, Elena García-Arumí, et al.Pageof 1